

DUSA Pharmaceuticals to Present at Roth Capital Partners 23rd Annual OC Growth Stock Conference
WILMINGTON, Mass.--([ BUSINESS WIRE ])--DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 23rd Annual OC Growth Stock Conference. The conference is being held at the Ritz-Carlton Laguna Niguel, Dana Point, California on March 13-16, 2011. Mr. Doman is scheduled to present at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 15, 2011. Interested parties can access the live webcast of the presentation at [ www.dusapharma.com ]. An archived version of the presentation will be available on the DUSA website approximately three hours following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products. Levulan® Kerastick® for topical solution plus DUSAa™s BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA also markets other dermatology products, including ClindaReach®. DUSA is based in Wilmington, Mass. Please visit our website at [ www.dusapharma.com ].